Zeng Huanling, Li Xin, Chen Shengli, Xu Jiajian, Xiao Yue, Zhao Yuhua
Department of Oncology, Xiaolan People's Hospital of Zhongshan (The Fifth People's Hospital of Zhongshan), Zhongshan, China.
Anticancer Drugs. 2025 Sep 1;36(8):678-681. doi: 10.1097/CAD.0000000000001731. Epub 2025 May 12.
Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is a rare subtype of inflammatory myofibrosarcoma. Anlotinib has demonstrated efficacy in the treatment of sarcoma. Nevertheless, to our knowledge, its use in EIMS has not been reported. Herein, we present a case of pulmonary EIMS. The patient underwent two courses of chemotherapy with doxorubicin combined with ifosfamide; however, the treatment was switched to anlotinib due to leukocytopenia. After 11 months of treatment with anlotinib, the tumor was in partial remission. Subsequently, the patient developed an acute myocardial infarction, which resulted in the discontinuation of anlotinib. Four months after discontinuation, the tumor progressed and anlotinib therapy was resumed. Following treatment for 5 months, tumor assessment indicated partial remission until March 2024. During this period, the patient experienced an adverse effect (i.e. ostealgia), which led to two reductions in the dosage of anlotinib. This case report provides a novel strategy for treating EIMS.
上皮样炎性肌成纤维细胞肉瘤（EIMS）是炎性肌纤维肉瘤的一种罕见亚型。安罗替尼已显示出在肉瘤治疗中的疗效。然而，据我们所知，其在EIMS中的应用尚未见报道。在此，我们报告一例肺部EIMS病例。该患者接受了两疗程阿霉素联合异环磷酰胺化疗；然而，由于白细胞减少，治疗改为安罗替尼。使用安罗替尼治疗11个月后，肿瘤部分缓解。随后，患者发生急性心肌梗死，导致安罗替尼停药。停药4个月后，肿瘤进展，恢复安罗替尼治疗。治疗5个月后，肿瘤评估显示部分缓解直至2024年3月。在此期间，患者出现了一种不良反应（即骨痛），导致安罗替尼剂量两次减少。本病例报告为治疗EIMS提供了一种新策略。
